153 related articles for article (PubMed ID: 32577159)
1. Loss of TRP53 (p53) accelerates tumorigenesis and changes the tumor spectrum of SJL/J mice.
Branca JA; Low BE; Saxl RL; Sargent JK; Doty RA; Wiles MV; Dumont BL; Hasham MG
Genes Cancer; 2020; 11(1-2):83-94. PubMed ID: 32577159
[TBL] [Abstract][Full Text] [Related]
2. Chromosome stability, in the absence of apoptosis, is critical for suppression of tumorigenesis in Trp53 mutant mice.
Liu G; Parant JM; Lang G; Chau P; Chavez-Reyes A; El-Naggar AK; Multani A; Chang S; Lozano G
Nat Genet; 2004 Jan; 36(1):63-8. PubMed ID: 14702042
[TBL] [Abstract][Full Text] [Related]
3. Selection for loss of p53 function in T-cell lymphomagenesis is alleviated by Moloney murine leukemia virus infection in myc transgenic mice.
Baxter EW; Blyth K; Cameron ER; Neil JC
J Virol; 2001 Oct; 75(20):9790-8. PubMed ID: 11559812
[TBL] [Abstract][Full Text] [Related]
4. Comparison of properties of spontaneous and radiation-induced mouse thymic lymphomas: role of Trp53 and radiation.
Kubota T; Yoshikai Y; Tamura Y; Mishima Y; Aoyagi Y; Niwa O; Kominami R
Radiat Res; 2005 Feb; 163(2):159-64. PubMed ID: 15658891
[TBL] [Abstract][Full Text] [Related]
5. Suppression of thymic lymphomas and increased nonthymic lymphomagenesis in Trp53-deficient mice lacking inducible nitric oxide synthase gene.
Tatemichi M; Tazawa H; Masuda M; Saleem M; Wada S; Donehower LA; Ohgaki H; Ohshima H
Int J Cancer; 2004 Oct; 111(6):819-28. PubMed ID: 15300793
[TBL] [Abstract][Full Text] [Related]
6. Genetic mapping of a putative tumor suppressor locus that influences tumorigenesis and metastasis in mice.
Ayanga B; Price R; Gu X; Lozano G; Evans SC
Genes Chromosomes Cancer; 2006 Jul; 45(7):668-75. PubMed ID: 16586494
[TBL] [Abstract][Full Text] [Related]
7. Heterozygosity for p53 (Trp53+/-) accelerates epithelial tumor formation in fanconi anemia complementation group D2 (Fancd2) knockout mice.
Houghtaling S; Granville L; Akkari Y; Torimaru Y; Olson S; Finegold M; Grompe M
Cancer Res; 2005 Jan; 65(1):85-91. PubMed ID: 15665282
[TBL] [Abstract][Full Text] [Related]
8. Aflatoxin B1 and/or hepatitis B virus induced tumor spectrum in a genetically engineered hepatitis B virus expression and Trp53 haploinsufficient mouse model system for hepatocarcinogenesis.
Cullen JM; Brown DL; Kissling GE; Foley JF; Rizzo J; Marion PL; Parron VI; French JE
Toxicol Pathol; 2009 Apr; 37(3):333-42. PubMed ID: 19258306
[TBL] [Abstract][Full Text] [Related]
9. Neural tube development requires the cooperation of p53- and Gadd45a-associated pathways.
Patterson AD; Hildesheim J; Fornace AJ; Hollander MC
Birth Defects Res A Clin Mol Teratol; 2006 Feb; 76(2):129-32. PubMed ID: 16470852
[TBL] [Abstract][Full Text] [Related]
10. Loss of heterozygosity occurs via mitotic recombination in Trp53+/- mice and associates with mammary tumor susceptibility of the BALB/c strain.
Blackburn AC; McLary SC; Naeem R; Luszcz J; Stockton DW; Donehower LA; Mohammed M; Mailhes JB; Soferr T; Naber SP; Otis CN; Jerry DJ
Cancer Res; 2004 Aug; 64(15):5140-7. PubMed ID: 15289317
[TBL] [Abstract][Full Text] [Related]
11. Pubertal and adult windows of susceptibility to a high animal fat diet in Trp53-null mammary tumorigenesis.
Zhu Y; Aupperlee MD; Zhao Y; Tan YS; Kirk EL; Sun X; Troester MA; Schwartz RC; Haslam SZ
Oncotarget; 2016 Dec; 7(50):83409-83423. PubMed ID: 27825136
[TBL] [Abstract][Full Text] [Related]
12. The Trp53 hemizygous mouse in pharmaceutical development: points to consider for pathologists.
Floyd E; Mann P; Long G; Ochoa R
Toxicol Pathol; 2002; 30(1):147-56. PubMed ID: 11890468
[TBL] [Abstract][Full Text] [Related]
13. Oxidative and nitrative stress caused by subcutaneous implantation of a foreign body accelerates sarcoma development in Trp53+/- mice.
Tazawa H; Tatemichi M; Sawa T; Gilibert I; Ma N; Hiraku Y; Donehower LA; Ohgaki H; Kawanishi S; Ohshima H
Carcinogenesis; 2007 Jan; 28(1):191-8. PubMed ID: 16857722
[TBL] [Abstract][Full Text] [Related]
14. Cis lethal genetic interactions attenuate and alter p53 tumorigenesis.
Wang Y; Zhang W; Edelmann L; Kolodner RD; Kucherlapati R; Edelmann W
Proc Natl Acad Sci U S A; 2010 Mar; 107(12):5511-5. PubMed ID: 20212136
[TBL] [Abstract][Full Text] [Related]
15. A transactivation-deficient mouse model provides insights into Trp53 regulation and function.
Jimenez GS; Nister M; Stommel JM; Beeche M; Barcarse EA; Zhang XQ; O'Gorman S; Wahl GM
Nat Genet; 2000 Sep; 26(1):37-43. PubMed ID: 10973245
[TBL] [Abstract][Full Text] [Related]
16. MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment.
Fang DD; Tang Q; Kong Y; Wang Q; Gu J; Fang X; Zou P; Rong T; Wang J; Yang D; Zhai Y
J Immunother Cancer; 2019 Nov; 7(1):327. PubMed ID: 31779710
[TBL] [Abstract][Full Text] [Related]
17. Chromosome 11 allelotypes reflect a mechanism of chemical carcinogenesis in heterozygous p53-deficient mice.
Hulla JE; French JE; Dunnick JK
Carcinogenesis; 2001 Jan; 22(1):89-98. PubMed ID: 11159746
[TBL] [Abstract][Full Text] [Related]
18. Rapid viral induction of murine lymphomas in the graft-versus-host reaction.
Cornelius EA
J Exp Med; 1972 Dec; 136(6):1533-44. PubMed ID: 4404880
[TBL] [Abstract][Full Text] [Related]
19. Genetic interactions between tumor suppressors Brca1 and p53 in apoptosis, cell cycle and tumorigenesis.
Xu X; Qiao W; Linke SP; Cao L; Li WM; Furth PA; Harris CC; Deng CX
Nat Genet; 2001 Jul; 28(3):266-71. PubMed ID: 11431698
[TBL] [Abstract][Full Text] [Related]
20. p53 Mediates Vast Gene Expression Changes That Contribute to Poor Chemotherapeutic Response in a Mouse Model of Breast Cancer.
Tonnessen-Murray C; Ungerleider NA; Rao SG; Wasylishen AR; Frey WD; Jackson JG
Transl Oncol; 2018 Aug; 11(4):930-940. PubMed ID: 29852458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
